Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Medexus Pharmaceuticals Inc.
  6. News
  7. Summary
    MDP   CA58410Q2036

MEDEXUS PHARMACEUTICALS INC.

(MDP)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Medexus Pharmaceuticals : Stock Listing to Move to the Toronto Stock Exchange.

06/15/2021 | 04:13pm EDT


© MT Newswires 2021
All news about MEDEXUS PHARMACEUTICALS INC.
07/19CAREDX : Medexus Appoints New Chief Financial Officer
AQ
07/19Medexus Pharmaceuticals Inc. Announces Management Changes
CI
07/12MEDEXUS PHARMACEUTICALS : in Licensing Agreement For Treosulfan in Canada
MT
07/12Medexus Pharmaceuticals and medac GmbH enter into Licensing Agreement for Fir..
GL
07/12Medexus Pharmaceuticals and medac GmbH Enter into Licensing Agreement for Fir..
CI
07/07MEDEXUS PHARMACEUTICALS : Virtually Opens The Market
AQ
06/28Medexus Receives Notice of Compliance to Commercialize Treosulfan in Canada
GL
06/28Medexus Pharmaceuticals Inc. Receives Notice of Compliance to Commercialize T..
CI
06/17MEDEXUS PHARMACEUTICALS INC.(TSXV : MDP) dropped from S&P/TSX Venture Composite ..
CI
06/16Medexus Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended..
CI
More news
Financials
Sales 2022 127 M 102 M 102 M
Net income 2022 -14,7 M -11,8 M -11,8 M
Net Debt 2022 - - -
P/E ratio 2022 -11,6x
Yield 2022 -
Capitalization 140 M 112 M 112 M
Capi. / Sales 2022 1,11x
Capi. / Sales 2023 0,86x
Nbr of Employees 24
Free-Float 91,4%
Chart MEDEXUS PHARMACEUTICALS INC.
Duration : Period :
Medexus Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MEDEXUS PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 7,31 CAD
Average target price 12,38 CAD
Spread / Average Target 69,3%
EPS Revisions
Managers and Directors
Kenneth d’Entremont Chief Executive Officer & Director
Marcel Konrad Chief Financial Officer
Peter A. van der Velden Chairman
Richard Labelle VP-Allergy, Pediatric & OTC Portfolios
Michael Peter Mueller Independent Director
Sector and Competitors
1st jan.Capi. (M$)
MEDEXUS PHARMACEUTICALS INC.6.72%112
JOHNSON & JOHNSON9.42%453 313
ROCHE HOLDING AG13.38%337 105
PFIZER, INC.16.30%239 637
NOVARTIS AG0.28%225 343
ELI LILLY AND COMPANY44.22%221 348